Literature DB >> 32757421

Shielding against SARS-CoV-2 infection is not justified in children with severe asthma.

Michael Kabesch1,2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32757421      PMCID: PMC7436748          DOI: 10.1111/pai.13327

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   5.464


× No keyword cloud information.
To the Editor, For the EU‐funded project PERMEABLE (PERsonalized MEdicine Approach for asthma and allergy Biologicals SeLEction), which addresses the availability of and access to advanced therapy of asthma in children across Europe, we performed a survey including 37 major pediatric asthma and allergy centres between September 2019 and July 2020. In total, the centres contributing to the survey treated approximately 1.000 young patients with severe asthma in 25 major European countries and Turkey with biologicals. In the light of the corona pandemic, we extended our survey asking the responsible clinicians whether they experienced a SARS‐CoV‐2 infection in any of the children they are caring for. The questions pertaining to corona infections were asked between March and July 2020. Given the prevalence of SARS‐CoV‐2 infections in the general population and in children, one would expect that at least 1% of the patients would be affected . In fact, none of the centres was aware of any symptomatic COVID‐19 case in their patient populations or any positive SARS‐CoV‐2 tests. This leads to the conclusion that either SARS‐CoV‐2 infections have a mild or even asymptomatic course also in children with severe asthma or that children with severe asthma (and their parents) were extremely successful in avoiding SARS‐CoV‐2 infections. Thus, we investigated by structured interview how centres in those 26 countries had instructed their patients to avoid COVID‐19. Interestingly, only four European countries (UK, Ireland, Portugal and Malta) had a strict, so‐called shielding policy in place which followed a principle of maximal segregation of severe asthmatics from the rest of the population: not leaving the house at all, not attending school even when they reopened, wearing face masks also at home and social distancing even with family members. All other countries followed the principle of continuing or even enforcing asthma treatment in patients and advising to follow the same corona rules as the general population. Both strategies led to the same result: an absence of COVID‐19 cases in children with severe asthma. We conclude from this observation that shielding is not necessary in children with severe asthma as they and their families are perfectly able to avoid corona infections. The harm done to children by enforcing seclusion, separation and stigmatization needs to be acknowledged. Deprivation of school, social contact and friends weights heavy on children and the absence of any COVID‐19 cases in major European centres for severe asthma in children do not justify a policy of compulsory shielding of children with severe asthma, neither in the first nor in any further corona wave.

FUNDING INFORMATION

PERMEABLE is funded by EU Grant 779282 and BMBF Grant 01KU1909A.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1111/pai.13327.
  1 in total

1.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.

Authors:  Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Hélène Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Sabine Yerly; Isabelle Arm Vernez; Olivia Keiser; Samia Hurst; Klara M Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Gétaz; François Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous
Journal:  Lancet       Date:  2020-06-11       Impact factor: 79.321

  1 in total
  3 in total

1.  Trends in SARS-CoV-2 seroprevalence amongst urban paediatric patients compared with a nationwide cohort in the Netherlands.

Authors:  I L M Rotee; D S Y Ong; J G M Koeleman; E R A Vos; G A Tramper-Stranders
Journal:  J Clin Virol Plus       Date:  2021-10-09

2.  Comments on nitric oxide in children with asthma, low-dose oral immunotherapy for cow's milk allergy, and SARS-Cov-2 testing in school children.

Authors:  Philippe Eigenmann
Journal:  Pediatr Allergy Immunol       Date:  2021-05       Impact factor: 6.377

Review 3.  Facts and Challenges about Asthma and COVID-19 among the Paediatric Population: A Systematic Literature Review.

Authors:  Emilia Moreno-Sánchez; Estefanía Castillo-Viera; Emilia Vélez-Moreno; Francisco-Javier Gago-Valiente
Journal:  Medicina (Kaunas)       Date:  2021-11-29       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.